Stockreport

Ascletis Completes Enrollment of Phase III Trial of ASC40 (Denifanstat) Once-Daily Oral Tablet for Treatment of Acne

Sagimet Biosciences Inc.  (SGMT) 
PDF -Phase III trial enrolled a total of 480 patients with moderate to severe acne-Topline results expected in the second quarter 2025HANGZHOU, China, Nov. 12, 2024 /PRNewsw [Read more]